A randomized HARMONi-A analysis published in JAMA reports that ivonescimab, a bispecific antibody, added to chemotherapy improved outcomes in EGFR-variant non–small cell lung cancer. The JAMA publication frames the study as a step toward building combination regimens that target tumor-associated pathways while maintaining chemotherapy backbone intensity. While the provided article excerpt does not include the full efficacy and safety tables, the inclusion of a bispecific agent in a randomized trial design signals increasing confidence in multispecific immuno-oncology approaches for molecularly defined lung cancer populations. For biotech teams, the key takeaway is that bispecifics continue to move beyond early-phase expansion cohorts into comparative settings that can influence how future treatment standards are sequenced.